Jenscare Scientific's LuX-Valve Plus Transcatheter Tricuspid Valve Replacement System Receives EU MDR CE Certification

China's medical-device industry is steadily expanding its footprint in global cardiovascular markets, and Jenscare Scientific Co., Ltd. just cleared one of the most rigorous regulatory hurdles in Europe.

The Ningbo-based company announced that its LuX-Valve Plus transcatheter tricuspid valve replacement system has obtained European Union Medical Device Regulation (MDR) CE certification — a milestone that allows the device to be marketed and sold across the 27-nation bloc.

The certification marks a significant step for Jenscare as it pushes to establish its structural-heart technology on the world stage. Tricuspid valve disease affects millions globally, yet treatment options remain limited. Transcatheter tricuspid valve replacement is widely regarded as one of the most complex frontiers in interventional cardiology, and gaining EU MDR CE clearance signals that the LuX-Valve Plus system has met the bloc's stringent safety and performance standards.

The EU MDR framework, which replaced the older Medical Device Directive, is considered among the most demanding regulatory regimes for medical devices worldwide. Achieving certification under MDR — rather than the legacy MDD — demonstrates compliance with heightened clinical-evidence and post-market-surveillance requirements.

For Jenscare, the approval opens the door to commercialization across Europe and could serve as a springboard into other regulated international markets. The company has positioned itself as a pioneer in transcatheter valve therapies, and the LuX-Valve Plus system represents its flagship offering in the rapidly evolving structural-heart space.

The European tricuspid intervention market is still in its early stages, with a handful of players racing to bring devices to clinicians and patients. Jenscare's CE certification adds a Chinese-made system to that short list — a development that could reshape competitive dynamics in a therapeutic area where unmet need remains substantial.